共 126 条
[1]
Shean K(2013)Drug-associated adverse events and their relationship with outcomes in patients receiving treatment for extensively drug-resistant tuberculosis in South Africa PLoS One 8 407-412
[2]
Streicher E(2018)Global programmatic use of bedaquiline and delamanid for the treatment of multidrug-resistant tuberculosis Int J Tuberc Lung Dis. 22 723-732
[3]
Pieterson E(2014)Multidrug-resistant tuberculosis and culture conversion with bedaquiline N Engl J Med 371 1393-1400
[4]
Symons G(2013)Delamanid improves outcomes and reduces mortality in multidrug-resistant tuberculosis Eur Respir J 41 887-893
[5]
van Zyl Smit R(2015)Classification of antituberculosis drugs: a new proposal based on the most recent evidence Eur Respir J 46 1315-1318
[6]
Theron G(2014)Initial experience of bedaquiline use in a series of drug-resistant tuberculosis patients from India Int J Tuberc Lung Dis. 18 S241-S249
[7]
Cox V(2012)New Drugs for the Treatment of Tuberculosis: Needs, Challenges, Promise, and Prospects for the Future The Journal of Infectious Diseases 205 1601799-570
[8]
Brigden G(2016)Long-term outcome and safety of prolonged bedaquiline treatment for multidrug-resistant tuberculosis European Respiratory Journal 49 561-60
[9]
Crespo RH(2000)Marginal structural models to estimate the causal effect of zidovudine on the survival of HIV-positive men Epidemiol (Cambridge, Mass) 11 56-12
[10]
Lessem E(2015)Access to new medications for the treatment of drug-resistant tuberculosis: patient, provider and community perspectives Int J Infect Dis 32 249-28